DDI09.SS.PharmaDA.wave4

DDI09.SS.PharmaDA.wave4 -...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
34ba03ff93f9806cd5f0191fb16f7418ed0776e6.doc Dartmouth 2K9 1 Pharma D/A Pharma D/A. .............................................................................................................................................. 1 1NC. ......................................................................................................................................................... 2 Uniqueness Ext. . ........................................................................................................................................ 4 Link ext. .................................................................................................................................................... 5 Bioterror Internal Link Ext. ......................................................................................................................... 6 Bioterror Impact Ext. . ................................................................................................................................ 7 Innovation 2NC. ......................................................................................................................................... 8 Econ 2NC. ................................................................................................................................................. 9 Last printed 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
34ba03ff93f9806cd5f0191fb16f7418ed0776e6.doc Dartmouth 2K9 2 1NC Despite the recent economic downturn U.S. pharmaceutical companies are still experiencing high growth Reuters ‘9 (May 13 th 2009, Reuters, ‘Learns about the U.S. pharmaceutical Industry Report, 2008-2009, http://www.reuters.com/article/pressRelease/idUS140811+13-May-2009+BW20090513 ) The United States has the largest pharmaceutical industry in the world . In 2007, its pharmceutical revenue totaled at US$ 315 billio n. In the past decades, the structure of American pharmaceutical industry has changed dramatically caused by the aging of population, the emerging of bio-pharmaceutical technology and fierce global competition. The key players in the United States including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, etc. American pharmaceutical companies paid great attention to R & D due to the free at US $65.2 billion, up 3.16% of last year. Healthcare reform collapses the pharmaceutical industry The Economist, ’08 (December 13, 2008, Winds of change; Pharmaceuticals, lexis) Perhaps surprisingly, PhRMA now supports most aspects of health-care reform being mooted, from universal coverage to restructuring the insurance market. However, this acceptance of change goes only so far. Push Merck officials on the prospects for drug-price controls , and their unflinching answer is that they are "completely opposed" to
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 9

DDI09.SS.PharmaDA.wave4 -...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online